The biotechnology sector is undergoing significant transformation, characterized by major technological innovations and substantial economic challenges. The "patent cliff," representing a potential loss of $400 billion, is driving companies to rapidly innovate to offset patent losses. Artificial Intelligence (AI) plays a central role in this transformation, facilitating drug discovery and optimizing research and development (R&D) processes. Recent fundraising and strategic partnerships highlight the growing interest in AI within this sector.